Aloha, MauiBound, it is funny, isn't it - for some here it's not enough that Amarantus multiplies its market cap in the months ahead. No, AMBS must progress according to a precise schedule. I really should keep quiet as I hope to capitalize on any raised expectations and subsequent short-term disappointment ... moving funds now, and hoping to buy cheaper shares soon.

I've spent two decades working in a creative industry where deadlines constantly shift for various reasons and I imagine that biotech may be similar in that regard. I don't know if corporate milestones are more predictable in financial and insurance businesses, but I'm guessing yes and that might explain some of the attitudes here.